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fDITORIAL COMMENT
ascular Brachytherapy
nd Coronary Stenting
or De Novo Lesions
ove on the Rocks*
on Waksman, MD, FACC
ashington, DC
lthough vascular brachytherapy (VBT) has proved to be
ffective and safe for the treatment of in-stent restenosis
1–8), its role in the treatment of de novo lesions remains
nclear. The clinical trials that were designed to study the
ffectiveness of various beta radiations for the treatment of
e novo coronary lesions reported mixed results. Although
easibility studies such as the Beta Energy Restenosis Trial
BERT) (9), which used 90Sr/Y, the Proliferation Reduc-
ion and Vascular Energy trial (10), which used P-32, and
he Dose-Finding Study (11), which used a Y-90 emitter,
uggested the efficacy and safety of beta radiation for the
revention of restenosis of de novo lesions, the pivotal
etaCath study failed to demonstrate efficacy and raised
uestions about the safety of using VBT, especially as
djunct therapy to the coronary stenting of de novo lesions
12).
See pages 520 and 528
The main pitfalls of the BetaCath study were its high
ncidence of late thrombosis, which was controlled with the
dministration of prolonged antiplatelet therapy, and the
dge effect stenosis phenomenon, which was attributed to
eographical miss and insufficient coverage of the injured
argins with a sufficient radiation dose (12). As a result,
eta-radiation therapy was abound for the prevention of
estenosis for de novo lesions and was restricted for the
revention of the recurrence of in-stent restenosis.
During the last two years there have been several attempts
o revisit and study the possibility of using VBT for the
reatment of de novo lesions. These studies were inconclu-
ive and had mixed results. The two studies presented in this
ssue of the Journal, by Serruys et al. (13) and Sabate´ et al.
14), were designed to study the impact of VBT on stented
oronary arteries and attempted to implement lessons from
revious VBT studies with an emphasis on prolonged
ntiplatelet therapy—a minimum of six months—and the
voidance of geographical miss. Whereas the Beta-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Washington Hospital Center, Washington, DC. Dr. Waksman is
ntitled to royalties from vascular brachytherapy devices used for the prevention of
testenosis.adiation Investigation with Direct stenting and Galileo in
urope (BRIDGE) study was a multicentered study con-
ucted on patients with single lesions18 mm, the study by
abate´ et al. (14) was a single-center study that focused on
iabetic patients.
The strength of these studies was that they were prospec-
ive, randomized, controlled trials that both chose a primary
nd point reflecting the impact of beta irradiation on
eointimal proliferation at six months, either by angio-
raphic intrastent late loss by quantitative coronary angiog-
aphy in the BRIDGE study or by or intravascular ultra-
ound alone in the study by Sabate´ et al. (14). Both studies
ad small patient cohorts and were underpowered to detect
econdary end points such as clinical events. Nevertheless,
oth studies met their primary end points, although these
ere not translated to clinical utility. In both the BRIDGE
tudy and the study by Sabate´ et al. (14), a significant
eduction in the neointimal volume was noted in the
adiation group, which resulted in significantly lower late
oss when compared with the controls. Furthermore, the
bsolute neointimal volume in the irradiated group of the
abate´ et al. (14) study was even lower when compared with
he neointimal volume of the patients in the BRIDGE
tudy, in which only 15% had diabetes. Thus, these results
onfirm observations from previous studies reporting that
ascular radiation therapy continues to be an effective
herapy in the diabetic populations as well (15).
The authors of the BRIDGE study claim that direct
tenting and the use of glycoprotein IIb/IIIa blockers
ptimized all procedural steps with radiation therapy. To
ate, however, there are no reports supporting that these
dditional features do indeed optimize radiation therapy. In
act, direct stenting and the use of glycoprotein IIb/IIIa
ailed to affect restenosis rates with metallic stents and
rug-eluting stents. In contrast, the key factors considered
ssential in improving the results of VBT are adequate
osimetry and radiation coverage with wide margins to
void geographical miss (16,17) and prolonged antiplatelet
herapy to prevent late thrombosis. Nevertheless, the exe-
ution of these features was far from optimal; in the
RIDGE study, 21% of vessels had documented geograph-
cal miss, suggesting misplacement of the source in relation
o the stent position. This rate of geographical miss is
nexpected because 32-mm sources are supposed to cover
tents of 18 mm with no geographic miss.
The authors of the BRIDGE study disclosed that at least
hree patients from the radiation group had stent thrombo-
is related to premature clopidogrel withdrawal, which
uggests that these patients were not under optimal man-
gement with antiplatelet therapy in relation to VBT. For
atients undergoing VBT today, it is recommended that
hey be given clopidogrel for at least 6 months (preferably
or 12 months) for cardiac event reduction (18).
Similarly, in the Sabate´ et al. (14) study, most of the
arget vessel revascularization was an edge effect that oc-
c
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August 4, 2004:538–40 Editorial Commenturred because of geographical miss. All late thrombosis
vents occurred as a result of clopidogrel withdrawal. There-
ore, although the intent of these two studies was to treat
atients with VBT under full optimization at every step,
hose steps were poorly executed and resulted in undesired
vents such as edge effect and late thrombosis.
The authors of both studies claim that despite the
ignificant reduction of late loss in-stent, this result did not
ranslate into clinical utility in terms of angiographic reste-
osis, target lesion, and vessel revascularization reduction. It
s important to remember that these studies were not
owered to detect differences in clinical events between the
wo treatments arms. However, the lack of any difference
etween the two groups and the late thrombosis that led to
cute myocardial infarction events in the irradiated group
aise a legitimate question: Can we marry stents and
adiation for the prevention of restenosis of de novo lesions?
he data from the present studies and previous studies,
ncluding the stented arm of the BetaCath study, indicate
hat the marriage between these two promising technologies
s problematic and resembles a “love on the rocks” kind of
elationship.
In an attempt to address this question and to resolve the
dge effect, we preformed a series of preclinical studies in
hich stents were placed in porcine coronaries and were
rradiated with different doses and different radiation mar-
ins. We reported that the edge effect can be eliminated
hen stents are placed in non-injured vessels and irradiated
f the radiation margins are at least 15 mm in length from
he injured segment and a higher dose of nearly 20% is
rescribed (19). It is possible that the radiation margins used
n the BRIDGE and Sabate´ et al. (14) studies (10 mm)
ere not sufficient to eliminate the edge effect.
The major complication in the presented studies was the
resence of late thrombosis, which led to acute myocardial
nfarction and death. From other studies, we know that this
omplication can be controlled and nearly eliminated with
rolonged antiplatelet therapy. In the stented arm of the
etaCath study, late thrombosis was eliminated with a
rolonged antiplatelet therapy of at least 60 days, but the
oses prescribed in the present studies were higher and
herefore required a longer duration of the antiplatelet
herapy, perhaps a minimum of 12 months.
In the Saphenous Vein Graft Beta Radiation to Prevent
n-Stent Restenosis study (20), radiation was used in de
ovo saphenous vein graft lesions, the majority of which
ere stented and irradiated with adequate margins and
rolonged antiplatelet therapy (a minimum of six months).
low recurrence rate and absence of late thrombosis were
eported.
Nevertheless, with the introduction of drug-eluting
tents, the strategy of stenting and radiation for the preven-
ion of restenosis of de novo coronary lesions has become
utile and may be valid only for insulin-requiring diabetic
atients, who are reported to have higher rates of restenosis
n the pivotal studies of drug-eluting stents (21). In contrast,adiation therapy was associated with the same results for
iabetic patients as for non-diabetic patients, and its ability
o reduce neointima formation after metallic stenting also
as demonstrated in the study of diabetic patients by Sabate´
t al. (14). Thus, only a comparison of drug-eluting stents to
adiation therapy with bare metal stenting will determine
hich of the two approaches is preferable. If diabetic
atients continue to experience restenosis with drug-eluting
tents, this may merit a study to examine the safety of a
ombination therapy of VBT and drug-eluting stenting.
Therefore, with the dissemination of drug-eluting stents
or the treatment of de novo lesions, the only role left for
BT in the treatment of de novo lesions remains as adjunct
herapy for non-stented lesions. The data for the treatment
f non-stented lesions with VBT are favorable and are
eported in numerous studies, including BERT (9), the
ose-Finding Study (11), the balloon arm of the BetaCath
tudy (12), and the Re-188 liquid-filled balloon study (22).
ll demonstrated that VBT resulted in acceptable outcomes
hen applied to de novo lesions. In these studies, the
adiation arm performed better, with less restenosis and
ith the potential for favorable remodeling, when compared
ith the control arm. Even if we fix the edge effect and
liminate the late thrombosis phenomenon, it would be
ifficult to justify the use of VBT as adjunct therapy for
tenting as an alternative to drug-eluting stents. However,
ith its ability to inhibit neointima formation, the role of
BT in the treatment of de novo lesions will be limited to
he non-stented ones—whether pretreated with balloon or
ther non-stented devices.
eprints requests and correspondence: Dr. Ron Waksman,
ashington Hospital Center, 110 Irving Street, NW, Suite 4B-1,
ashington, DC 20010. E-mail: ron.waksman@medstar.net.
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